Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Research highlights from the International Journal of Nanomedicine 2014

Authors Mian SH, Patel N, Shah F, Arja SB, Shiekh F

Received 17 January 2015

Accepted for publication 19 January 2015

Published 31 March 2015 Volume 2015:10(1) Pages 2503—2505


Checked for plagiarism Yes

Sarah H Mian, Neel A Patel, Farina Shah, Sateesh B Arja, Farooq A Shiekh

Department of Basic Medical Sciences, Avalon University School of Medicine, Curaçao, Netherlands Antilles

Can nanocarriers conquer gene therapy?
Evaluation of: Magalhães M, Farinha D, Pedroso de Lima MC, Faneca H. Increased gene delivery efficiency and specificity of a lipid-based nanosystem incorporating a glycolipid. Int J Nanomedicine. 2014;9:4979–4989.
Hepatocellular carcinoma (HCC) is a devastating disease that makes up 70%–85% of all cases of liver cancer, affecting millions of people worldwide.1 Unfortunately, HCC is aggressive and deadly; patients typically live for only 6 to 20 months after diagnosis, highlighting the dire need for new effective therapies. Although gene therapy has the potential to offer new biologically based medicines, the efficient, selective, and safe delivery of DNA- or RNA-based drugs to target cells including hepatocytes is still a major limiting factor to the broad applications of gene therapy in cancer diseases.2–4

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]